Merck KGaA builds a manufacturing and distribution platform in Asia

| By | Investments, Merck KGaA, Pharmaceutical Manufacturing
0
181

Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced an additional investment of $47 million to build a robust manufacturing and distribution platform in Asia over a span of two years. This investment follows the company’s November 2016 announcement of its $95 million Life Science investment in Nantong, China.

The rapidly growing biopharmaceutical industry in South Korea makes the country one of the key Life Science hubs in Asia. Merck KGaA, Darmstadt, Germany’s new manufacturing and distribution center, located in the Songdo district of Incheon, will include an infrastructure to facilitate the supply of its products to customers in Korea and advanced cell culture media manufacturing capabilities. The new site is expected to be fully operational in Q4 2019.

The new manufacturing and distribution centr, located in Mumbai, is expected to be completed in 2019. Occupying 10 acres, the site is more than 129,000 square feet with added capacity to meet future growth, further improving inventory availability and reducing lead times.

China, with a burgeoning biosimilar market, is fast becoming a biotech powerhouse. Single-use technologies provide increased flexibility and efficiency which are critical for biosimilar development and manufacturing. This investment, to accelerate Merck KGaA, Darmstadt, Germany’s Mobius® single-use manufacturing, addresses the growing biopharmaceutical demand in China. The site will be ready in 2018, and is expected to reduce lead time by at least 50 percent.

SOURCE: merck kgaa
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.